What is the optimal preventive therapy for a patient with near‑daily migraine attacks and a history of cerebral infarction?

Optimal Preventive Therapy for Near-Daily Migraine with History of Cerebral Infarction

This patient requires preventive therapy with topiramate or candesartan as first-line options, while strictly avoiding all vasoactive medications including triptans, ergots, and beta-blockers due to the history of cerebral infarction.

Critical Contraindications in This Patient

Given the history of cerebral infarction (migrainous infarction), certain standard migraine preventive medications are absolutely contraindicated:

• Avoid all triptans and ergots - these vasoactive medications can precipitate further ischemic events 1
• Avoid beta-blockers (propranolol, timolol, metoprolol) - despite being first-line in typical migraine, the vasoconstrictive properties pose stroke risk
• Avoid combination oral contraceptives if female - increases stroke risk in migraine patients with prior infarction

Recommended First-Line Preventive Options

Primary Recommendation: Topiramate

• Dosing: Start 25-50 mg daily, titrate slowly to 50-100 mg daily 2, 3
• Rationale: No vasoconstrictive properties, proven efficacy for high-frequency migraine
• Monitoring: Watch for cognitive side effects, kidney stones, glaucoma
• Timeline: Assess efficacy after 2-3 months 3

Alternative First-Line: Candesartan (ARB)

• Dosing: Start low and titrate as tolerated 2, 3
• Rationale: Angiotensin receptor blockers are safe post-stroke and may provide vascular protection
• Additional benefit: Blood pressure control if hypertensive

Second-Line Options

If first-line agents fail or are not tolerated:

Amitriptyline

• Dosing: 10-30 mg at night, titrate to 30-150 mg daily 2, 4
• Advantage: Particularly effective if comorbid tension-type headache or sleep disturbance 4
• Caution: Anticholinergic effects, weight gain, drowsiness

Flunarizine

• Dosing: 5-10 mg daily 2
• Caution: Monitor for parkinsonism and depression

Third-Line: CGRP Monoclonal Antibodies

If conventional preventives fail after adequate trials:

• Erenumab (70-140 mg subcutaneous monthly) 2
• Fremanezumab (225 mg monthly or 675 mg quarterly) 2
• Note: Fremanezumab specifically not recommended in patients with history of stroke, subarachnoid hemorrhage, or coronary heart disease 2

Critical Management Principles

Acute Treatment Modifications

• Use NSAIDs only (ibuprofen, naproxen, diclofenac) for acute attacks 5, 2
• Absolutely avoid triptans for acute treatment despite near-daily attacks 1
• Add antiemetics (metoclopramide, domperidone) as needed 2

Antiplatelet Therapy

• Maintain aspirin or other antiplatelet for secondary stroke prevention 1
• This serves dual purpose: stroke prevention and acute migraine treatment

Medication Overuse Headache Risk

With near-daily migraines, this patient is at extremely high risk for medication overuse headache:

• Limit acute medication use to <10 days/month for triptans (not applicable here)
• Limit NSAIDs to <15 days/month 5
• Aggressive preventive therapy is essential to reduce attack frequency

Treatment Algorithm

1. Initiate topiramate 25 mg daily, increase by 25 mg weekly to target 75-100 mg daily
2. Continue antiplatelet therapy (aspirin 81-325 mg daily)
3. Acute treatment: NSAIDs + antiemetic only
4. Assess at 8-12 weeks: If <50% reduction in headache days, add or switch to candesartan
5. If both fail: Trial amitriptyline (avoid if cardiac conduction issues)
6. Refractory cases: Consider CGRP antibodies, but avoid fremanezumab given stroke history 2

Common Pitfalls to Avoid

• Do not use standard first-line beta-blockers - the stroke history changes the risk-benefit calculation
• Do not prescribe triptans even if attacks are severe - use NSAIDs with antiemetics instead
• Do not use valproate/divalproex if patient is female of childbearing potential 2
• Do not expect immediate results - preventive medications require 2-3 months for full effect 3
• Do not overlook lifestyle modifications - hydration, regular sleep, stress management, regular aerobic exercise 5

Monitoring Strategy

• Headache diary: Track frequency, severity, acute medication use
• Reassess at 2-3 months: Aim for ≥50% reduction in monthly migraine days
• Long-term: After 6-12 months of stability, consider tapering preventive therapy 2
• Neuroimaging: Consider repeat imaging if new neurological symptoms develop

The history of cerebral infarction fundamentally alters the treatment approach, prioritizing non-vasoconstrictive preventive agents and eliminating triptans from the therapeutic arsenal 1, 6.